ModifiedUnitedHealthcarePolicy CS016.O

Chelation Therapy

This policy governs the clinical use and coverage considerations for chelation therapy for heavy metal toxicity/overload and for non-overload indications; it affects providers and members covered by UnitedHealthcare where this policy is applicable.

Policy Summary

PayerUnitedHealthcare

PolicyChelation Therapy

Policy CodePolicy CS016.O

Change TypeClarification of coverage for overload indicationsreferences updated

Effective DateAug 1, 2025

Next Review Date

Key ActionPrior authorization must document validated laboratory evidence of metal overload and appropriate specialist evaluation before chelation is approved.

SourceLink

POLICY UPDATE CHANGES

Replaced language that previously excluded discussion of chelation for heavy metal toxicity and overload conditions with language stating such uses are proven and medically necessary.

Updated Clinical Evidence and References sections to reflect the most current information.

Application Kentucky and Louisiana: updated reference link to reflect the current title for state-specific policy version.

2distinct indication categories discussed (overload vs non-overload)

1,708TACT trial participants

41%RRR in diabetes subgroup (TACT)

small

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

quality of most non-overload studies

poisoning/overload onlyFDA approval stance

Coverage Criteria for Chelation Therapy

Chelation for Heavy Metal Toxicity/Overload

Covered when ALL of the following are met for heavy metal overload:

Demonstrated overload: Objective diagnosis of heavy metal overload (e.g., iron, copper, lead, aluminum, mercury) based on appropriate testing and reference values

Diagnostic workup must consider the individual's history, appropriate testing methods, and use of accurate and specific reference values

Agent selection and administration: Use of an established chelating agent delivered by route/method appropriate for the agent and toxicity level

Medication, route, method, and site of administration vary depending on agent and toxicity

Chelation for Non-Overload Conditions

Not supported/insufficient evidence for non-overload conditions

Lack of demonstrated toxicity: Conditions without demonstrated acute or chronic heavy metal toxicity (e.g., cardiovascular disease, rheumatoid arthritis, diabetes, cancer, Alzheimer's disease, Parkinson's disease) lack quality evidence supporting chelation therapy

Health technology assessments and systematic reviews found studies small, heterogeneous, and methodologically weak

Covered: Documented metal intoxication/overload

Covered when ALL of the following are met

Documented metal overload: Objective, validated laboratory evidence of clinically relevant metal intoxication or overload (for example, blood lead level meeting treatment thresholds or documented iron overload) using accepted tests and specimensper standard toxicology/hematology guidelines

See documentation requirements for validated testing and appropriate biological samples

Appropriate specialist involvement: Evaluation and recommendation by an appropriate specialty (e.g., medical toxicology, hematology) supporting chelation for documented metal overloadn/a

Specialty organizations (ACMT) recommend chelation only for documented intoxication

Not Medically Necessary / Not Covered: Non-overload and unproven uses

Not covered when ANY of the following are present

Non-overload chronic conditions: Use of chelation therapy to treat chronic progressive diseases (cardiovascular disease, atherosclerosis, diabetes, cancer, Alzheimer's disease, autism spectrum disorder, Parkinson's disease, rheumatoid arthritis, multiple sclerosis, osteoarthritis, osteoporosis, and other listed conditions) due to insufficient or conflicting evidence of efficacyn/a

Multiple systematic reviews and specialty organizations do not support use

Experimental or unproven indications: Chelation intended to remove 'undesirable metabolites or toxins' or to treat conditions without validated diagnostic evidence of metal overload or without demonstrated patient-centered benefitn/a

Studies are small/heterogeneous and do not demonstrate clinical benefit

Chelation challenge testing:

Investigational / Research Considerations

Investigational / research-only considerations

TACT and subgroup signals: TACT trial and subsequent subgroup analyses showed exploratory signals (e.g., diabetes subgroup, anterior MI) but findings are hypothesis-generating and require replicationn/a

Authors and reviewers call for replication trials such as TACT2 before routine use for CVD

Ongoing or future trials: Ongoing or planned randomized trials (for example, TACT2) may clarify efficacy in defined subgroups; until replicated, chelation for CVD remains unsupported for routine coveragen/a

Consider coverage only within formal clinical trial settings per payer policy

Medically necessary uses

Covered when ALL of the following are met

FDA-approved indications: Use is for FDA-approved indications (documented metal poisoning or iron overload) as referenced in a recognized drug compendium

Document diagnosis and relevant laboratory/biologic testing per compendium and FDA guidance

Supporting documentation: Clinical documentation confirms diagnosis with validated tests and justifies chelation agent selection

Avoid use for autism, CVD, or other non-overload conditions based on lack of evidence and specialty guidance

Not medically necessary

Not covered when ANY of the following are present

Non-overload conditions: Intended use to prevent or treat cardiovascular disease, autism spectrum disorder, or neurodegenerative conditions (for example, Alzheimer's disease)

Professional societies (ACC/AHA, ACMT, Canadian Cardiovascular Society) find no evidence of benefit or recommend against use

Lack of diagnostic confirmation: No validated testing documenting metal intoxication/overload

Chelation for unproven indications is considered not medically necessary

No quality, peer‑reviewed evidence supports the use of chelation therapy for a broad group of non‑overload conditions. Systematic reviews and health technology assessments have concluded studies in these conditions are generally small, heterogeneous, and methodologically weak, and do not demonstrate consistent patient‑centered benefit.

Examples of non‑overload conditions referenced in the literature include autism spectrum disorder, Alzheimer’s disease, and Parkinson’s disease. Clinical trials and systematic reviews show no convincing evidence of clinical benefit for these indications, and available studies are often underpowered or inconclusive.

Use of chelation therapy for conditions other than objectively documented metal intoxication or overload (for example, autism or cardiovascular disease) is excluded from coverage due to insufficient and conflicting evidence of efficacy and documented safety concerns with inappropriate use.

Chelation for chronic, progressive diseases and other non‑overload indications is not supported by well‑designed peer‑reviewed studies and is therefore considered not medically necessary in the absence of validated evidence of metal overload.

Chelation therapy to treat chronic progressive diseases including cardiovascular disease is not supported outside of strict investigational contexts; professional societies and evidence reviews recommend limiting chelation to cases with documented metal intoxication diagnosed using validated tests.

Attempts to use chelation to improve symptoms such as angina or exercise tolerance, or to treat neurodegenerative conditions (including attempts to treat autism), are considered not medically necessary because guideline panels and systematic reviews do not find sufficient evidence of benefit.

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Reference codes — Prior Authorization May Be Required

Prior authorization may be required for chelation agents and related services. When PA is required, the request must demonstrate that the requested agent and route of administration are being used for an FDA-recognized indication (e.g., documented metal poisoning or iron overload) or meet the policy’s medical necessity criteria.

Providers should confirm payer-specific PA submission processes and include required clinical documentation with the request.

Prior Authorization

Prior Authorization for FDA-Indicated Chelation

Prior authorization is required to demonstrate that chelation is being used for FDA-recognized indications or other medically supported indications documented in this policy (for example, confirmed lead poisoning or iron overload). FDA approval alone is informational and not a guarantee of coverage; PA documentation must tie the requested treatment to the specific FDA indication or to policy-defined medical necessity.

Include citation to the drug compendium indication (e.g., AHFS or DrugDex) and relevant FDA labeling.

Billing and Procedure Codes

Consolidated reference HCPCS/J/Procedure codesmixed

J0470	Injection, dimercaprol, per 100 mg.
J0600	Injection, edetate calcium disodium, up to 1,000 mg.
J0895	Injection, deferoxamine mesylate, 500 mg.
J3490	Unclassified drugs.
J3520	Edetate disodium, per 150 mg.
J8499	Prescription drug, oral, nonchemotherapeutic, NOS.
M0300	IV chelation therapy (chemical endarterectomy).
S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

Definitions and Key Terms

Chelation therapy — definition

DefinitionChelation therapy involves administering molecules (natural or synthetic) that bind specific metal toxins to facilitate their excretion; the medication, route, method, and site of administration vary by agent, toxicity level, and clinical indication.

Typical targetsCommonly treated metals include iron, copper, lead, aluminum, and mercury.

Clinical requirementUsed when heavy metal overload is accurately diagnosed based on appropriate testing and specific reference values.

Agent/administration variabilityChoice of chelating agent and dose depends on the metal involved and severity of toxicity; routes include intravenous and oral depending on agent.

PurposePrimary goal is to bind and remove metal ions to reduce toxicity and prevent organ damage.

Background and Evidence Summary

Chelation therapy is an established treatment to remove specific metal toxins in patients with accurately diagnosed heavy metal overload (for example, iron, copper, lead, aluminum, or mercury). When objective, validated laboratory evidence of clinically relevant metal intoxication exists, chelating agents can facilitate binding and excretion of the offending metal and provide substantial clinical benefit.

Policy Revision History

2025-09-01revision

Updated state-specific policy reference link for Kentucky and Louisiana.

2025-08-01revisionLatest

Revised title and replaced prior language to state that chelation for heavy metal toxicity/overload is proven and medically necessary; updated Clinical Evidence and References sections and archived previous policy version CS016.N.

Policy Summary

PayerUnitedHealthcare

PolicyChelation Therapy

Policy CodePolicy CS016.O

Change TypeClarification of coverage for overload indicationsreferences updated

Effective DateAug 1, 2025

Next Review Date

Key ActionPrior authorization must document validated laboratory evidence of metal overload and appropriate specialist evaluation before chelation is approved.

SourceLink

On This Page

Use of 'chelation challenge' urinary analyses for diagnosing lead poisoning or determining need for chelation therapy

Chemo-challenge testing is not clinically useful and may be hazardous; AAP recommends against chelation challenge for children

Autism chelation: Pharmaceutical chelation for autism spectrum disordern/a

No evidence of benefit and reports of serious adverse events (hypocalcemia, renal impairment, death) — risks outweigh benefits

If the request is for an off-label use, include robust clinical justification and evidence meeting the policy’s criteria (see documentation callouts).

Billing Rule

Billing / Code Inclusion Is Not Coverage Assurance

Billing and inclusion of codes in this section are for reference only and do not constitute a determination of coverage or payment. Providers are responsible for ensuring that billed services meet the policy’s coverage criteria and any applicable state or contractual requirements. Claims inconsistent with coverage criteria or lacking required documentation may be denied.

If services are billed, maintain documentation that supports medical necessity per this policy to avoid denials.

Documentation Required

Required Diagnostic Documentation for True Metal Intoxication

For requests of chelation for suspected or confirmed metal intoxication/overload, prior authorization and medical record documentation must include validated diagnostic testing in appropriate biological samples and clear laboratory evidence of overload or toxicity.

Specific laboratory test results using validated methods (e.g., blood lead level for lead; serum ferritin, liver iron concentration by MRI, or cardiac T2* for iron overload).
Date of test(s) and reference ranges used by the reporting laboratory.
Relevant clinical history and exposure assessment (source, duration, and likelihood of exposure).
Any prior treatments and response (e.g., prior chelation episodes, changes in metal burden).

Documentation Required

Documentation of Indication

Documentation must clearly identify the indication for chelation therapy and support it with objective evidence. For FDA-approved indications, reference the specific FDA-labeled indication and provide relevant compendium or labeling citations. For non-FDA or off‑label requests, include detailed clinical rationale, peer-reviewed evidence, and documentation that standard guideline‑directed therapies have been considered or tried when applicable.

Statement of the precise diagnosis/indication (e.g., 'acute lead poisoning with BLL = X µg/dL', or 'transfusional iron overload with LIC = Y mg Fe/g dry weight').
Supporting objective data (lab values, imaging, biopsy results) with dates and laboratory reference ranges.
Reference to FDA labeling or drug compendium entry for the requested agent when used for an FDA indication.
If requesting treatment for non-overload conditions, provide peer-reviewed evidence and justify why the patient meets criteria despite limited evidence; note such requests carry high risk of denial.

Non-overload condition — definition

DefinitionNon-overload condition: clinical conditions in which acute or chronic heavy metal toxicity has not been demonstrated and chelation is hypothesized to provide benefit, but evidence is lacking.

ExamplesIncludes proposals to use chelation for cardiovascular disease, rheumatoid arthritis, cancer, diabetes, Alzheimer’s disease, Parkinson’s disease, and others.

Evidence summaryWell-designed, peer-reviewed studies do not support chelation for chronic progressive non-overload diseases; studies are small, heterogeneous, and methodologically weak.

Policy implicationChelation for non-overload conditions is considered investigational or not medically necessary absent documented metal overload.

EDTA (edetate disodium) — definition and approval scope

AgentEDTA (edetate disodium / disodium EDTA) is a chelating agent referenced in cardiovascular trials (e.g., TACT) and discussed in guideline statements.

Scope of approvalDisodium EDTA is FDA-approved for specific indications such as iron overload and lead poisoning but is not approved for preventing or treating cardiovascular disease.

Clinical trial useEDTA (as part of the TACT infusion protocol) was the chelating agent evaluated in the large TACT randomized trial (n = 1,708) for prior myocardial infarction patients.

GuidanceProfessional societies note EDTA should be reserved for documented intoxication and not for routine CVD prevention/treatment.

Iron chelators — definition and examples

DefinitionIron chelators are medications that bind iron to facilitate removal from the body.

ExamplesAgents include deferasirox and deferiprone (DFP); deferoxamine is another commonly used iron chelator referenced elsewhere in the document.

Clinical usesStudied and used for iron overload (e.g., in hemochromatosis or transfusional iron overload) and investigated experimentally in conditions such as Parkinson disease and in hemodialysis patients.

Evidence noteSome trials (e.g., small PD studies) show biologic changes (reduced regional brain iron) but are inconclusive for patient-centered outcomes; deferasirox showed ferritin reductions in hemodialysis iron-overloaded patients with unclear clinical significance.

Chelation therapy (general) — administration and FDA approval scope

DefinitionChelation therapy: administration of chelating agents (e.g., disodium EDTA, deferoxamine, deferasirox) to bind and remove metals from the body.

FDA approval scopeFDA-approved uses for chelating agents are limited to metal poisoning and iron overload; FDA approval alone is informational and not a coverage guarantee.

Safety considerationsChelating drugs can cause significant adverse effects (dehydration, hypocalcemia, kidney injury, liver enzyme elevations, hypotension, allergic reactions, and essential mineral deficiencies); inappropriate use poses substantial risks.

Documentation requirementUse should be supported by validated diagnostic tests and appropriate specialty evaluation when for documented intoxication/overload.